Aripiprazole, olanzapine and haloperidol pamoate salts
US6987111B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 6, 2003 |
| Grant date | Jan 17, 2006 |
| Priority date | — |
| Expiry date | May 10, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/18
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the discovery that pamoate salts of haloperidol and aripiprazole result in a good to superior long acting and/or extended release profile. Thus, in one aspect of the invention, the invention includes pamoate salts of haloperidol or aripiprazole. Preferably, the pamoate salt is characterized by a ratio of haloperidol to pamoate of 1:1 or 2:1. The pamoate salt can be crystalline, such as a needle or a dense crystal, such as described in the Figures.The invention further relates to methods of treating an individual in need thereof comprising administering a pharmaceutical composition comprising a pamoate salt of haloperidol and aripiprazole.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.